Header Logo

Connection

DAVID GRAHAM to Proton Pump Inhibitors

Back to Details
This is a "connection" page, showing publications DAVID GRAHAM has written about Proton Pump Inhibitors.
DAVID GRAHAM
Connection Strength
18.192
Proton Pump Inhibitors
  1. Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker-Based Dual, Triple, and Quadruple Regimens for First-Line Helicobacter pylori Infection Treatment: A Systematic Review and Network Meta-Analysis. Am J Gastroenterol. 2025 Apr 01; 120(4):787-798.
    View in: PubMed
    Score: 0.758
  2. Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study. Helicobacter. 2021 Jun; 26(3):e12801.
    View in: PubMed
    Score: 0.595
  3. Recent Developments Pertaining to H. pylori Infection. Am J Gastroenterol. 2021 01 01; 116(1):1-3.
    View in: PubMed
    Score: 0.586
  4. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance. J Gastroenterol Hepatol. 2021 May; 36(5):1159-1163.
    View in: PubMed
    Score: 0.575
  5. Stress Ulcer Prophylaxis for ICU Patients. JAMA. 2020 07 07; 324(1):101.
    View in: PubMed
    Score: 0.567
  6. Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter. 2019 Feb; 24(1):e12554.
    View in: PubMed
    Score: 0.506
  7. Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer. BMJ Evid Based Med. 2018 06; 23(3):111-112.
    View in: PubMed
    Score: 0.484
  8. Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. Gastroenterology. 2018 07; 155(1):67-75.
    View in: PubMed
    Score: 0.483
  9. Update on the Use of Vonoprazan: A Competitive Acid Blocker. Gastroenterology. 2018 Feb; 154(3):462-466.
    View in: PubMed
    Score: 0.477
  10. Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency. Clin Gastroenterol Hepatol. 2018 06; 16(6):800-808.e7.
    View in: PubMed
    Score: 0.467
  11. Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now? Saudi J Gastroenterol. 2017 Sep-Oct; 23(5):265-267.
    View in: PubMed
    Score: 0.465
  12. New Insight Into an Effective Treatment of Marginal Ulceration After Roux-en-Y Gastric Bypass. Clin Gastroenterol Hepatol. 2017 04; 15(4):501-503.
    View in: PubMed
    Score: 0.444
  13. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. Dig Dis Sci. 2016 11; 61(11):3215-3220.
    View in: PubMed
    Score: 0.436
  14. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016 06; 14(6):577-85.
    View in: PubMed
    Score: 0.424
  15. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016 May; 65(5):870-8.
    View in: PubMed
    Score: 0.417
  16. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016 05; 150(5):1113-1124.e5.
    View in: PubMed
    Score: 0.417
  17. Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis. World J Gastroenterol. 2015 Dec 07; 21(45):12954-62.
    View in: PubMed
    Score: 0.412
  18. How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. Gastroenterol Clin North Am. 2015 Sep; 44(3):537-63.
    View in: PubMed
    Score: 0.399
  19. Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second line regimen in the presence of levofloxacin resistance. Aliment Pharmacol Ther. 2015 Jun; 41(11):1220-1.
    View in: PubMed
    Score: 0.398
  20. High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections. Helicobacter. 2014 Aug; 19(4):319-22.
    View in: PubMed
    Score: 0.367
  21. Helicobacter pylori: tailored therapy with novel sequential quadruple therapies. Nat Rev Gastroenterol Hepatol. 2013 Jan; 10(1):6-8.
    View in: PubMed
    Score: 0.334
  22. Treatment of Helicobacter pylori in Latin America. Lancet. 2012 Feb 04; 379(9814):408; author reply 408-9.
    View in: PubMed
    Score: 0.316
  23. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J Clin Gastroenterol. 2011 Apr; 45(4):309-13.
    View in: PubMed
    Score: 0.298
  24. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011 Apr; 16(2):139-45.
    View in: PubMed
    Score: 0.298
  25. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am. 2010 Sep; 39(3):465-80.
    View in: PubMed
    Score: 0.286
  26. Helicobacter pylori infection. N Engl J Med. 2010 08 05; 363(6):595-6; author reply 596.
    View in: PubMed
    Score: 0.285
  27. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol. 2010 Jan; 8(1):36-41.e1.
    View in: PubMed
    Score: 0.269
  28. Long-term proton pump inhibitor use and gastrointestinal cancer. Curr Gastroenterol Rep. 2008 Dec; 10(6):543-7.
    View in: PubMed
    Score: 0.254
  29. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs. 2008; 68(6):725-36.
    View in: PubMed
    Score: 0.238
  30. Failures in a proton pump inhibitor therapeutic substitution program: lessons learned. Dig Dis Sci. 2007 Oct; 52(10):2813-20.
    View in: PubMed
    Score: 0.226
  31. Early heartburn relief with proton pump inhibitors and the marketing of zegreid. Clin Gastroenterol Hepatol. 2005 Oct; 3(10):1047; author reply 1047.
    View in: PubMed
    Score: 0.204
  32. Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer. Dig Dis Sci. 2005 Jul; 50(7):1185-93.
    View in: PubMed
    Score: 0.200
  33. Proton pump inhibitors and the risk of gastric cancer: a systematic review, evidence synthesis and life course epidemiology perspective. BMJ Open Gastroenterol. 2025 Apr 19; 12(1).
    View in: PubMed
    Score: 0.197
  34. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003 May 15; 17(10):1229-36.
    View in: PubMed
    Score: 0.173
  35. Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates. Dig Dis Sci. 2023 05; 68(5):1691-1697.
    View in: PubMed
    Score: 0.170
  36. Response to: a true point-of-care molecular testing method for tailored therapy for Helicobacter pylori eradication. Expert Rev Gastroenterol Hepatol. 2023 03; 17(3):311.
    View in: PubMed
    Score: 0.170
  37. Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther. 2003 Jan; 17(2):193-200.
    View in: PubMed
    Score: 0.168
  38. Quality of Studies for Gastric pH Measurements With Vonoprazan. Am J Gastroenterol. 2022 11 01; 117(11):1882.
    View in: PubMed
    Score: 0.166
  39. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002 Jan 28; 162(2):169-75.
    View in: PubMed
    Score: 0.158
  40. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology. 2021 08; 161(2):495-507.e4.
    View in: PubMed
    Score: 0.149
  41. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs. Am J Med. 2001 Jan 08; 110(1A):58S-61S.
    View in: PubMed
    Score: 0.147
  42. Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: A Double-Blind, Randomized, Controlled Trial. Ann Intern Med. 2020 06 16; 172(12):795-802.
    View in: PubMed
    Score: 0.140
  43. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter. 2020 Aug; 25(4):e12692.
    View in: PubMed
    Score: 0.140
  44. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment. Dig Dis Sci. 2020 12; 65(12):3639-3646.
    View in: PubMed
    Score: 0.138
  45. Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera? or Lactobacillus reuteri for treatment na?ve or for retreatment of Helicobacter pylori. Two randomized pilot studies. Helicobacter. 2019 Dec; 24(6):e12659.
    View in: PubMed
    Score: 0.134
  46. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial. Helicobacter. 2019 Aug; 24(4):e12596.
    View in: PubMed
    Score: 0.131
  47. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019 06; 49(11):1385-1394.
    View in: PubMed
    Score: 0.130
  48. Pantoprazole in Patients in the ICU. N Engl J Med. 2019 03 07; 380(10):984.
    View in: PubMed
    Score: 0.129
  49. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther. 2018 09; 16(9):679-687.
    View in: PubMed
    Score: 0.124
  50. Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2018 09; 16(9):1427-1433.
    View in: PubMed
    Score: 0.121
  51. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018 Jan; 33(1):37-56.
    View in: PubMed
    Score: 0.119
  52. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997 Oct; 11(5):935-8.
    View in: PubMed
    Score: 0.117
  53. Illusions regarding Helicobacter pylori clinical trials and treatment guidelines. Gut. 2017 12; 66(12):2043-2046.
    View in: PubMed
    Score: 0.117
  54. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol. 2017 07; 14(7):383-384.
    View in: PubMed
    Score: 0.114
  55. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleve Clin J Med. 2017 Apr; 84(4):310-318.
    View in: PubMed
    Score: 0.113
  56. Increasing role for modified bismuth-containing quadruple therapies for Helicobacter pylori eradication. Minerva Gastroenterol Dietol. 2017 06; 63(2):77-79.
    View in: PubMed
    Score: 0.111
  57. High-dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1996 Dec; 10(6):1001-4.
    View in: PubMed
    Score: 0.110
  58. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 01; 66(1):6-30.
    View in: PubMed
    Score: 0.109
  59. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015 Nov; 64(11):1715-20.
    View in: PubMed
    Score: 0.101
  60. Helicobacter pylori: New Thoughts and Practices. Gastroenterol Clin North Am. 2015 Sep; 44(3):xv-xvi.
    View in: PubMed
    Score: 0.100
  61. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015 Apr; 148(4):719-31.e3.
    View in: PubMed
    Score: 0.097
  62. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter. 2014 Jun; 19(3):207-13.
    View in: PubMed
    Score: 0.091
  63. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol. 2014 Jan; 8(1):21-8.
    View in: PubMed
    Score: 0.090
  64. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol. 2013 Oct; 25(10):1134-40.
    View in: PubMed
    Score: 0.089
  65. In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine. Digestion. 2012; 86(2):171-7.
    View in: PubMed
    Score: 0.082
  66. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol. 2012 May-Jun; 46(5):397-400.
    View in: PubMed
    Score: 0.080
  67. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter. 2011 Apr; 16(2):146-52.
    View in: PubMed
    Score: 0.075
  68. Empiric therapies for Helicobacter pylori infections. CMAJ. 2011 Jun 14; 183(9):E506-8.
    View in: PubMed
    Score: 0.074
  69. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol. 2011 Feb; 8(2):79-88.
    View in: PubMed
    Score: 0.074
  70. Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol. 2010 Aug; 45(8):816-20.
    View in: PubMed
    Score: 0.069
  71. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol. 2009 Feb; 7(2):145-8.
    View in: PubMed
    Score: 0.063
  72. Helicobacter pylori diagnosis and management. Gastroenterol Clin North Am. 2006 Jun; 35(2):229-47.
    View in: PubMed
    Score: 0.053
  73. Effects of amoxicillin dosage on cure rate, gut microbiota, and?antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial. Lancet Microbe. 2025 Mar; 6(3):100975.
    View in: PubMed
    Score: 0.048
  74. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment. Aliment Pharmacol Ther. 2004 May 15; 19(10):1051-61.
    View in: PubMed
    Score: 0.046
  75. Ulcers and gastritis. Endoscopy. 2004 Jan; 36(1):42-7.
    View in: PubMed
    Score: 0.045
  76. Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan. Helicobacter. 2023 Dec; 28(6):e13019.
    View in: PubMed
    Score: 0.044
  77. Controversies regarding management of Helicobacter pylori infections. Curr Opin Gastroenterol. 2023 11 01; 39(6):482-489.
    View in: PubMed
    Score: 0.044
  78. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol. 2003 May; 98(5):1005-9.
    View in: PubMed
    Score: 0.043
  79. Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. Am J Gastroenterol. 2023 07 01; 118(7):1184-1195.
    View in: PubMed
    Score: 0.043
  80. Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study. Front Immunol. 2022; 13:1049908.
    View in: PubMed
    Score: 0.042
  81. Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe. Am J Gastroenterol. 2023 02 01; 118(2):269-275.
    View in: PubMed
    Score: 0.041
  82. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020 12; 69(12):2093-2112.
    View in: PubMed
    Score: 0.036
  83. Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? J Dig Dis. 2018 Nov; 19(11):674-677.
    View in: PubMed
    Score: 0.032
  84. Risk factors for Barrett's esophagus compared between African Americans and non-Hispanic Whites. Am J Gastroenterol. 2014 Dec; 109(12):1870-80.
    View in: PubMed
    Score: 0.024
  85. Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. Am J Gastroenterol. 2013 Oct; 108(10):1576-83.
    View in: PubMed
    Score: 0.022
  86. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012 May; 61(5):646-64.
    View in: PubMed
    Score: 0.020
  87. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009 Apr; 14(2):109-18.
    View in: PubMed
    Score: 0.016
  88. Schatzki's ring: to cut or break an unresolved problem. Dig Dis Sci. 2004 Mar; 49(3):379-83.
    View in: PubMed
    Score: 0.011
  89. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Arch Intern Med. 2002 Oct 14; 162(18):2105-10.
    View in: PubMed
    Score: 0.010
  90. Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. Helicobacter. 1996 Dec; 1(4):243-50.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.